1. Introduction, Taxonomy {#sec1-dentistry-07-00085}
=========================

*Actinomyces species* (originating from the greek words *aktinos* (ray) and *mykes* (fungus), corresponding to the radial arrangement of the bacterial filaments) are members of anaerobic, non-spore-forming Gram-positive rods \[[@B1-dentistry-07-00085],[@B2-dentistry-07-00085]\]. Taxonomically, the genus *Actinomyces* is part of the *Actinomycetales* order of the Actinobacteria phylum (characterized by high guanine-cytosine (G+C) content in their genome, 55--68% in case of the *Actinomyces* genus) \[[@B3-dentistry-07-00085],[@B4-dentistry-07-00085]\]. The *Actinomycetales* order includes other clinically important genera, such as *Actinobaculum*, *Actinomadura*, *Corynebacterium*, *Cutibacterium* (previously *Propionibacterium*), *Frankia*, *Gardnerella*, *Mobiluncus*, *Nocardia*, and *Varibaculum*. The genera *Actinobaculum*, *Actinomyces*, *Mobiluncus*, and *Varibaculum* are the most similar phenotypically, as they share several characteristics (a highly pleomorphic morphology ranging from branching rods to coccobacilli, various levels of aerotolerance, and non-acid fast staining, which is an important differentiating factor from *Nocardia* species) distinct from the other members of the order \[[@B5-dentistry-07-00085],[@B6-dentistry-07-00085]\]. Nevertheless, several genera, including *Actinomyces*, *Frankia, Nocardia*, and *Streptomyces* are sometimes (incorrectly) referred to as the "*actinomycetes*" group in clinical practice, due to their similar radiating or branching morphologies (resembling hyphae) and the possession of reproductive asexual spores, typical for filamentous fungi \[[@B7-dentistry-07-00085],[@B8-dentistry-07-00085],[@B9-dentistry-07-00085]\]. The genus *Actinomyces* currently holds 49 species, of which more, than 26 species have been implicated in human clinical infections ([Table 1](#dentistry-07-00085-t001){ref-type="table"}), however this number may be a reported estimation only, as these pathogens were frequently misidentified before the introduction of current diagnostic technologies (e.g., DNA-DNA hybridization, polymerase chain reaction (PCR), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and next-generation sequencing (NGS)) \[[@B1-dentistry-07-00085],[@B3-dentistry-07-00085],[@B5-dentistry-07-00085],[@B7-dentistry-07-00085],[@B8-dentistry-07-00085],[@B10-dentistry-07-00085],[@B11-dentistry-07-00085]\].

Similarly to other non-spore-forming Gram-positive anaerobes, members of the *Actinomyces* genus are important saprophytic constituents of the normal microbiota of animals and humans \[[@B2-dentistry-07-00085],[@B12-dentistry-07-00085],[@B13-dentistry-07-00085]\]. These microorganisms are predominantly found in the human oropharynx, and they are abundantly present in gingival crevices, periodontal pockets, tonsillar crypts, as well as on carious teeth and in dental plaques \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B8-dentistry-07-00085],[@B11-dentistry-07-00085],[@B14-dentistry-07-00085]\]. In fact, \~30% of edentulous infants are colonized at the age of 2 months, while at the age of 12 months, \>90% of children harbored these microorganisms in their oral cavities; in these studies, *A. odontolyticus* was found to be the predominant member of the genus, while interestingly *A. israelii* (the major etiological agent in human infections) was uncommonly isolated \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B8-dentistry-07-00085],[@B11-dentistry-07-00085],[@B14-dentistry-07-00085]\]. Among the results of the National Institutes of Health (NIH) Human Microbiome Project (HMP), other species, such as *A. georgiae*, *A. gerencseriae*, *A. israelii*, *A. meyeri*, *A. naeslundii*, *A. odontolyticus*, *A. oricola*, and *A. radicidentis*, were also found in the resident flora of the human oral cavity \[[@B15-dentistry-07-00085]\]. In addition, *Actinomyces* species colonize the upper respiratory tract, gastrointestinal tract and female genital tract \[[@B2-dentistry-07-00085],[@B12-dentistry-07-00085],[@B13-dentistry-07-00085],[@B16-dentistry-07-00085]\]. In contrast, these microorganisms are not normally present on the surface of the skin, which is dominated by *Cutibacterium* (previously *Propionibacterium*) spp. and various staphylococci. This phenomenon may be due to the secretion of various molecules (fatty acids, antibacterial peptides) by the above mentioned microorganisms, detrimental to the survival of other species \[[@B17-dentistry-07-00085],[@B18-dentistry-07-00085]\].

2. Epidemiology, Clinical Presentation {#sec2-dentistry-07-00085}
======================================

*Actinomyces* infections in general are considered to be rare (with a reported annual incidence of 1/300,000 persons), however, the incidence of anaerobic Gram-positive rods may be underestimated/underreported, as many laboratories still do not have the capabilities or interest for their full diagnostic workup \[[@B5-dentistry-07-00085],[@B19-dentistry-07-00085]\]. Additionally, these microorganisms are slow-growing and have fastidious nutritional requirements, which further discourages some microbiology laboratories from their precise identification \[[@B20-dentistry-07-00085]\]. *Actinomyces* infections mainly occur among patients between 20 to 60 years of age, while the incidence is greater in males (male-to-female ratio: 3:1) with a peak between age 40--50 years \[[@B2-dentistry-07-00085],[@B5-dentistry-07-00085],[@B19-dentistry-07-00085],[@B21-dentistry-07-00085]\]. Only circumstantial evidence was found why males are affected more frequently than females, mainly associated with environmental factors, while no physiological/biochemical/hormonal correlation was described. No racial, seasonal, geographical, or occupational predilections are associated with the increased occurrence of actinomycoses, however, before the 1970s, an increased prevalence was noted in rural areas, compared to people living in urban environments (the observed prevalence was 10:1; cervicofacial and cutaneous actinomycosis: presumably due to poor hygiene, neglected health status, and low socioeconomic status; pelvic: in females, due to extended (\>5 years) use of intrauterine devices (IUDs) and inadequate knowledge level on sexual practices), especially in people working with farm animals \[[@B5-dentistry-07-00085],[@B19-dentistry-07-00085]\]. Anatomically, *Actinomyces* infections may be divided to cervicofacial (including central nervous system), abdominal, thoracic (including lung), pelvic, and cutaneous infections ([Table 2](#dentistry-07-00085-t002){ref-type="table"}), with cervicofacial infections (also known as 'lumpy jaw syndrome') being the most prevalent type in the clinical practice \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B11-dentistry-07-00085],[@B19-dentistry-07-00085],[@B21-dentistry-07-00085],[@B22-dentistry-07-00085],[@B23-dentistry-07-00085],[@B24-dentistry-07-00085],[@B25-dentistry-07-00085],[@B26-dentistry-07-00085],[@B27-dentistry-07-00085],[@B28-dentistry-07-00085],[@B29-dentistry-07-00085],[@B30-dentistry-07-00085],[@B31-dentistry-07-00085]\]. In addition, *Actinomyces* species were also described in unusual clinical presentations, such as abscesses of the breasts, groin, perianal, periaural area, and axillae; infections of knee and hip prostheses; and pericarditis \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B11-dentistry-07-00085],[@B19-dentistry-07-00085],[@B21-dentistry-07-00085],[@B22-dentistry-07-00085],[@B23-dentistry-07-00085],[@B24-dentistry-07-00085],[@B25-dentistry-07-00085],[@B26-dentistry-07-00085],[@B27-dentistry-07-00085],[@B28-dentistry-07-00085],[@B29-dentistry-07-00085],[@B30-dentistry-07-00085],[@B31-dentistry-07-00085]\].

Thoracic (and lung) actinomycosis is primarily caused by the aspiration of oral *Actinomyces* from saliva (usually presenting with pyogenic infections in the chest wall, ribs and spine), abdominal infections arise from bowel perforation or increased intestinal permeability (resulting in appendicitis and colonic or diverticular infections), pelvic actinomycosis is linked to the extensive (i.e., long term) use of IUDs, while cerebral actinomycosis is primary caused by cervicofacial surgeries or penetrative head trauma \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B11-dentistry-07-00085],[@B19-dentistry-07-00085],[@B21-dentistry-07-00085],[@B22-dentistry-07-00085],[@B23-dentistry-07-00085],[@B24-dentistry-07-00085],[@B25-dentistry-07-00085],[@B26-dentistry-07-00085],[@B27-dentistry-07-00085],[@B28-dentistry-07-00085],[@B29-dentistry-07-00085],[@B32-dentistry-07-00085]\]. Adequate and prompt detection of actinomycosis should be performed, as the associated mortality is between 0 and 28% \[[@B19-dentistry-07-00085]\]. Initiation of therapy in cervicofacial infections is also important for the containment of the infection, as in untreated cases, the pathogens may disseminate to distant organs---such as the brain, lungs, and gastrointestinal tract---resulting in concomitant infection \[[@B19-dentistry-07-00085],[@B21-dentistry-07-00085],[@B22-dentistry-07-00085],[@B23-dentistry-07-00085],[@B24-dentistry-07-00085],[@B25-dentistry-07-00085],[@B26-dentistry-07-00085],[@B27-dentistry-07-00085],[@B28-dentistry-07-00085],[@B29-dentistry-07-00085]\]. In fact, hematogenous spread of bacteria from cervicofacial infections are the second main causes of brain and lung actinomycoses \[[@B32-dentistry-07-00085],[@B33-dentistry-07-00085],[@B34-dentistry-07-00085],[@B35-dentistry-07-00085],[@B36-dentistry-07-00085]\]. *Actinomyces* species are frequently isolated from the bloodstream of patients, following dental extractions (transient bacteremia) or due to increased permeability of oral mucosa \[[@B37-dentistry-07-00085],[@B38-dentistry-07-00085]\]. This kind of *Actinomyces* bacteremia is transient and should be cleared from the bloodstream in individuals with a healthy immune system \[[@B39-dentistry-07-00085]\].

Cervicofacial actinomycosis (as well as *Actinomyces* infections in other anatomical regions) is characterized by a slowly progressing (indolent) infection, although in rare cases, a rapid and fulminant course of infection may also take place (especially in case of immunocompromised patients), which is caused by infiltration of *Actinomyces* species (present in the oral cavity) into damaged mucosal surfaces \[[@B11-dentistry-07-00085],[@B21-dentistry-07-00085]\]. This mucosal injury may be due to inadequate dental hygiene, various medical interventions (mainly dental extractions or cervicofacial surgery), or trauma \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B11-dentistry-07-00085],[@B19-dentistry-07-00085],[@B21-dentistry-07-00085],[@B22-dentistry-07-00085],[@B23-dentistry-07-00085],[@B24-dentistry-07-00085],[@B25-dentistry-07-00085],[@B26-dentistry-07-00085],[@B27-dentistry-07-00085],[@B28-dentistry-07-00085],[@B29-dentistry-07-00085],[@B32-dentistry-07-00085]\]. The general and disease-specific risk factors for developing cervicofacial actinomycosis is presented in [Table 3](#dentistry-07-00085-t003){ref-type="table"}. While the indolent/chronic form is a relatively painless process at first, patients with the acute/fulminant form may rapidly experience severe pain \[[@B11-dentistry-07-00085]\]. In these infections, chronic, granulomatous lesions develop, that over time become suppurative in character \[[@B5-dentistry-07-00085],[@B19-dentistry-07-00085]\]. These lesions usually form multiple large abscesses (*cold abscesses*), which are connected by sinus tracts. Sinuses may express a typical, thick yellow exudate, containing the characteristic sulfur granules of *Actinomyces* spp. These granules, which are primarily yellow (but become dark brown later on, due to the deposition of calcium-phosphate) contain masses of filamentous organisms, bound together by the calcium salts and biofilm (a protein--polysaccharide complex) \[[@B5-dentistry-07-00085],[@B19-dentistry-07-00085],[@B40-dentistry-07-00085]\]. These granules macroscopically resemble grains of sand (0.1--1 mm in diameter) and they are important diagnostic markers of *Actinomyces* species \[[@B5-dentistry-07-00085],[@B19-dentistry-07-00085]\]. The granulomatous lesions do not respect tissue borders, therefore in advanced stages (due to the infiltration of the muscles used in mastication and the jawbone; 10% of cases), severe pain, difficulties in chewing, trismus may also occur \[[@B11-dentistry-07-00085]\]. The affected tissues usually have a hard (some reports say woody) consistency, due to the corresponding fibrosis and scarring.

The disease is often characterized by non-specific febrile episodes, coughs, and sudden weight loss, while adenopathy is rarely observed. Laboratory findings may include leukocytosis, increased erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels \[[@B41-dentistry-07-00085],[@B42-dentistry-07-00085]\]. Of note, the time period between the onset of the (non-specific) symptoms and the clinical diagnosis may be very long (6--12 months), which corresponds to erosion and tissue damage in the affected area. The unspecific nature of the symptoms further delays patients in seeking medical attention \[[@B43-dentistry-07-00085]\]. During the formulation of diagnosis, the clinical presentation, previous medical history of the patient should be considered, together with the microbiological findings; the growth of *Actinomyces* species does not definitively confirm and the absence of the pathogens in culture does not definitively rule out the disease \[[@B41-dentistry-07-00085],[@B42-dentistry-07-00085],[@B43-dentistry-07-00085]\].

The clinical diagnosis of actinomycosis may be difficult as the clinical presentation of the signs/symptoms can mimic other pathologies, such as solid tumors, active *Mycobacterium tuberculosis* infections, nocardiosis, fungal infections, infarctions (in the lungs), or other granulomatous diseases \[[@B5-dentistry-07-00085],[@B21-dentistry-07-00085],[@B44-dentistry-07-00085],[@B45-dentistry-07-00085],[@B46-dentistry-07-00085]\]. Although *Actinomyces* species are the primary cause of actinomycoses, there are usually multiple bacterial species present in these lesions: these pathogens include oral facultative pathogens, such as *Aggregatibacter actinomycetemcomitans*, *Propionibacterium propionicum, Streptococcus vidirans* group, Gram-positive anaerobic cocci (GPAC), and Gram-negative anaerobic rods \[[@B9-dentistry-07-00085],[@B47-dentistry-07-00085],[@B48-dentistry-07-00085]\]. If the physicians observe suppurative lesions in the submandibular or perimandibular regions, draining sinus tracts along the jawline and neck, the suspicion of actinomycosis should arise, especially in the case of relapsing infections \[[@B5-dentistry-07-00085],[@B21-dentistry-07-00085],[@B44-dentistry-07-00085],[@B45-dentistry-07-00085],[@B46-dentistry-07-00085]\].

*Actinomyces* species have been implicated in two other cervicofacial pathologies, that were previously considered non-infectious diseases: bisphosphonate osteonecrosis of the jaw and osteoradionecrosis \[[@B5-dentistry-07-00085],[@B19-dentistry-07-00085],[@B49-dentistry-07-00085],[@B50-dentistry-07-00085],[@B51-dentistry-07-00085],[@B52-dentistry-07-00085]\]. In both cases, *Actinomyces* spp. and biofilm containing sulfur granules were detected in necrotic bone lesions, presumably further facilitating bone tissue damage. Radiation therapy is characterized by mucosal disruption and corticosteroid use, while bisphosphonate therapy in elderly patients is due to osteoporosis; both clinical situations usually correspond to patients with advanced age and severe underlying conditions, and these medical interventions may additionally facilitate the invasion of the jawbone by these pathogens (although the exact pathomechanism of these diseases is still not clear) \[[@B5-dentistry-07-00085],[@B19-dentistry-07-00085],[@B49-dentistry-07-00085],[@B50-dentistry-07-00085],[@B51-dentistry-07-00085],[@B52-dentistry-07-00085]\].

3. Pathogenesis of the Infection {#sec3-dentistry-07-00085}
================================

There is not much known about the virulence factors of anaerobic non-spore-forming Gram-positive bacteria \[[@B19-dentistry-07-00085]\]. Members of this group (including *Actinomyces* spp.) are considered to be low-grade pathogens, without possessing 'classical' virulence factors, such as exotoxins \[[@B13-dentistry-07-00085],[@B14-dentistry-07-00085],[@B18-dentistry-07-00085],[@B53-dentistry-07-00085],[@B54-dentistry-07-00085]\]. Consequently, these microorganisms can only cause disease if the normal mucosal barriers have been disrupted by exogenous or iatrogenic damage (e.g., surgical intervention, trauma, foreign bodies, concomitant infections), which explains why the mentioned predisposing factors are necessary for these infections to occur \[[@B14-dentistry-07-00085],[@B18-dentistry-07-00085],[@B53-dentistry-07-00085],[@B54-dentistry-07-00085]\]. As *Actinomyces* spp. are abundantly present in the normal flora of humans (especially in the oral microbiome), these infections are mainly endogenous \[[@B5-dentistry-07-00085],[@B14-dentistry-07-00085]\]. *Actinomycoses* infections of an exogenous source or interpersonal transmission were not been reported, apart from so-called "punch or knuckle" actinomycosis, corresponding to punching or biting injuries \[[@B55-dentistry-07-00085]\].

Due to their ability to cause chronic lesions, these microorganisms should have the ability to evade elimination by the immune system \[[@B3-dentistry-07-00085],[@B41-dentistry-07-00085]\]. It is hypothesized that the formation of dense, interlinked chains of branched bacteria in sulfur granules should act as an inhibitor of phagocytic clearance; however, this phenomenon was not detected in an animal model, where bacteria were quickly phagocytosed by host defenses \[[@B40-dentistry-07-00085],[@B56-dentistry-07-00085]\]. As *Actinomycosis* infections are usually polymicrobial, involving as many as 5--10 other bacterial species simultaneously, these multispecies (and sometimes multiphyla) communities are thought to contribute to the pathogenesis of these infections \[[@B57-dentistry-07-00085]\]. In polymicrobial infections, aerobic/facultative anaerobic bacteria enhance the survival of anaerobes by reducing the oxygen tension in the tissues, by the production of a capsule or toxins, damaging the mucosal barrier, enhancing the invasiveness of *Actinomyces* species \[[@B18-dentistry-07-00085],[@B56-dentistry-07-00085]\]. In addition, the destruction of host tissues is beneficial for these microbial communities, providing nutrients and Fe^2+^ ions for all members of the consortia \[[@B40-dentistry-07-00085],[@B56-dentistry-07-00085]\]. The presence of foreign bodies (associated with devitalized tissues) further increases the possibility of invasion \[[@B58-dentistry-07-00085]\]. Strong biofilm production has been described in case of *A. israelii*, *A. naeslundii*, and *A. viscosus*; the biofilm may have a role in the chronic nature of these infections and their recurrence, and protects against the diffusion of antibiotic molecules \[[@B19-dentistry-07-00085]\]. The role of several other commensal bacteria (e.g., streptococci, *Aggregatibacter actinomycetemcomitans*, *Eikenella corrodens*, *Haemophilus aprophilus*, and *P. propionicum*) has been noted in the inhibition of host defenses after a mucosal breach \[[@B9-dentistry-07-00085],[@B48-dentistry-07-00085]\].

In addition, the relevance of *A. odontolyticus*, *A. oris*, *A. naeslundii*, and *A. viscosus* in the formation of dental plaques was described: these microorganisms are so-called "early colonizers" and they have the ability to bind statherin and proline-rich proteins in the saliva by their fimbriae, allowing for their binding onto the surface of teeth \[[@B19-dentistry-07-00085],[@B33-dentistry-07-00085],[@B59-dentistry-07-00085],[@B60-dentistry-07-00085],[@B61-dentistry-07-00085],[@B62-dentistry-07-00085]\]. On these surfaces, they may also interact (co-aggregate) with other members of the dental plaque microorganisms (e.g., *Fusobacterium*, *Prevotella*, and *Veillonella* species). In the presence of fermentable carbohydrates, *Actinomyces* species also produce acid, leading to dental caries and tooth decay. The significance of these fimbriae is also pronounced in osteomyelitis, where they bind collagen and contribute to the pathogenesis of bone necrosis \[[@B63-dentistry-07-00085],[@B64-dentistry-07-00085],[@B65-dentistry-07-00085],[@B66-dentistry-07-00085]\]. It has been described that *A. meyeri* has a great propensity for hematogenous dissemination; however, no differentiating virulence factor has been identified \[[@B22-dentistry-07-00085],[@B35-dentistry-07-00085]\]. Similarly, several species (*A. naeslundii*, *A. odontolyticus*, *A. gerencseriae*, *A. neuii*, *A. turicensis*, and *A. radingae*) have been implicated in anatomically specific clinical syndromes, which may be mediated by some form of tissue tropism or specific virulence determinant \[[@B19-dentistry-07-00085],[@B33-dentistry-07-00085],[@B59-dentistry-07-00085],[@B60-dentistry-07-00085],[@B61-dentistry-07-00085],[@B62-dentistry-07-00085]\].

4. Isolation and Identification of *Actinomyces* spp. from Clinical Specimen {#sec4-dentistry-07-00085}
============================================================================

Isolation and identification of *Actinomyces* spp. is a very important step in the diagnostic procedure of this disease and laboratory confirmation of these infections is often difficult \[[@B5-dentistry-07-00085]\]. The gold standard for the diagnosis of cervicofacial actinomycosis is culture, histological examination of a tissue sample, pus or abscess. Similarly to other anaerobic pathogens, the best clinical specimens for isolation are tissue biopsy samples, deep needle aspirates, joint fluids, pus, root canal exudates, aseptically collected peripheral blood and subgingival plaque (or bone, if osteomyelitis is suspected); while cutaneous or mucosal swabs, sputum, bronchial washing liquid (except for MiniBAL) and urine (except for suprapubic bladder aspirates) are not suitable for identification \[[@B10-dentistry-07-00085]\]. In addition, *Actinomyces* needs to be isolated from anatomical areas possessing rich commensal microbiota, therefore special care needs to be taken during sample collection ([Figure 1](#dentistry-07-00085-f001){ref-type="fig"}) \[[@B67-dentistry-07-00085]\]. Depending on the infection site, *Actinomyces* may be co-isolated with normal commensals, such as members of the *Enterobacteriaceae*, *Staphylococcus* spp., *Streptococcus* spp., and *E. corrodens* among facultative anaerobes; and *A. actinomycetemcomitans, Bacteroides* spp., *Capnocytophaga* spp., *Prevotella* spp., and *Veilonella* spp. among anaerobes \[[@B18-dentistry-07-00085],[@B67-dentistry-07-00085],[@B68-dentistry-07-00085]\]. For this reason, isolation of *Actinomyces* from a sterile body site (or the isolation of a limited number of microorganisms) usually has clinical significance, while from other sample types, the isolation of these microorganisms can be considered as contamination (or their significance should be evaluated by the treating physician). If polymicrobial infections is suspected, obtaining pure cultures of all of the relevant organisms present should be attempted. Additionally, recent broad-spectrum antibiotics may also reduce microbial diversity, which may also be misleading \[[@B5-dentistry-07-00085],[@B10-dentistry-07-00085]\].

The use of anaerobic transport techniques and pre-reduced anaerobically sterilized (PRAS) media is essential for successful recovery of these microorganisms \[[@B18-dentistry-07-00085]\]. Although these pathogens are more tolerant to atmospheric oxygen than most anaerobic bacteria, *Actinomyces* often fail to grow aerobically; therefore, the culture plates should be incubated in strict anaerobic condition (especially for their primary isolation \[[@B5-dentistry-07-00085],[@B69-dentistry-07-00085]\]. This may be performed using anaerobic jars or boxes, with the help of GasPak™ sachets (convenient for smaller laboratories, but these should not be prematurely opened as this could result in an oxygen shock for anaerobic microorganisms) or anaerobic glove boxes (ideal for reference laboratories with large volume of samples, allows for manipulation and examination of samples in anaerobic atmosphere, expensive) \[[@B10-dentistry-07-00085],[@B18-dentistry-07-00085],[@B70-dentistry-07-00085]\]. Both enriched culture broth (brain--heart infusion) and non-selective and selective solid media (arginine--glycerine agar) should be used for the successful isolation of *Actinomyces* spp.; metronidazole may act a selective agent for most other anaerobes, while nalidixic acid should be used to eliminate facultative anaerobic Gram-negative bacteria \[[@B67-dentistry-07-00085],[@B71-dentistry-07-00085]\]. *Actinomyces* spp. are fastidious, slow-growing microorganisms, bacterial colonies may appear after 3--7 days; however, this may take up to 14 days, therefore extended incubation times should be applied before the final microbiological report is released \[[@B72-dentistry-07-00085]\]. The communication between the clinician and microbiologist is imperative in these cases, as the physicians should notify the laboratory about the suspicion of cervicofacial actinomycosis \[[@B43-dentistry-07-00085]\]. In case of bone involvement, even longer incubation is recommended, due to the reduced growth properties of bacteria in this niche \[[@B43-dentistry-07-00085]\]. Although it is important to note that in around \~50% of cases, culture results are negative, especially if the samples were taken after the onset of antimicrobial therapy (which is frequent following dental procedures or cervicofacial surgery) \[[@B20-dentistry-07-00085]\]. Presumptive identification of these microorganisms is based on their morphology (clumping in liquid culture, white colonies with a domed surface or molar tooth-shaped morphology on solid media, which may become irregular after an extended incubation time), Gram-stain morphology, acid-fast negativity, indole-negativity, and metronidazole-resistance \[[@B8-dentistry-07-00085],[@B67-dentistry-07-00085],[@B73-dentistry-07-00085]\]. Additional (species-level) identification may be performed in tertiary-care centers or anaerobic reference laboratories, using biochemical testing methods (e.g., in-house biochemical panels, API 20A, VITEK 2 ANC card), gas-liquid chromatography, molecular methods (DNA--DNA hybridization, PCR, 16S rRNA gene sequencing, and fluorescence in situ hybridization), and MALDI-TOF MS \[[@B51-dentistry-07-00085],[@B74-dentistry-07-00085],[@B75-dentistry-07-00085],[@B76-dentistry-07-00085],[@B77-dentistry-07-00085],[@B78-dentistry-07-00085]\]. Serology is of no relevance in the diagnosis of actinomycosis \[[@B5-dentistry-07-00085],[@B21-dentistry-07-00085],[@B41-dentistry-07-00085]\].

The use of MALDI-TOF MS for diagnostic purposes has revolutionized routine clinical microbiology, and this is especially true for the identification of anaerobic bacteria \[[@B79-dentistry-07-00085],[@B80-dentistry-07-00085],[@B81-dentistry-07-00085],[@B82-dentistry-07-00085]\]. MALDI-TOF MS has allowed for the correct and precise identification of anaerobes in a clinically-relevant time frame, right after the appearance of the bacterial colonies on agar media, reducing the turnaround time for the processing of individual samples (compared to conventional, biochemical-based methods) \[[@B83-dentistry-07-00085],[@B84-dentistry-07-00085]\]. Currently, two major MALDI-TOF MS systems are available: the Microflex MALDI-TOF MS (Bruker Daltonik GmbH, Bremen, Germany) and the VITEK MS MALDI-TOF (bioMérieux) \[[@B85-dentistry-07-00085],[@B86-dentistry-07-00085]\]. Both of these instruments utilize a database of existing reference spectra (Biotyper for Bruker (Bruker Daltonik GmbH, Bremen, Germany) and Saramis for bioMérieux (bioMérieux, Marcy-l'Étoile, France)) \[[@B85-dentistry-07-00085]\]. Several studies have reported on the identification efficacy of *Actinomyces* using direct inoculation onto the MALDI-TOF stainless steel plate; however, on-plate extraction with 70% ethanol or formic acid or a complete extraction before the MALDI-TOF measurements has increased the rate of species-level identification for Gram-positive anaerobes \[[@B87-dentistry-07-00085]\]. However, there are currently no studies detailing on the clinical impact (i.e., benefit) of species-level identification of *Actinomyces* species, as the therapeutic approach for these infections is very similar, irrespective of the species of the pathogen \[[@B88-dentistry-07-00085],[@B89-dentistry-07-00085]\].

The macroscopic and direct microscopic examination of pus collected from the suspected lesions is of critical importance in the diagnosis of actinomycosis \[[@B5-dentistry-07-00085]\]. As the colony counts of these microorganisms is usually low in pus, a large volume of sample or several samples should be collected and examined. Sulfur granules are suggestive of the presence of *Actinomyces* spp., while contamination may be suspected in the absence of these granules and a typical clinical syndrome, however, it is not specific enough for definitive diagnosis (they are absent in \~50% of samples, and similar granules may be observed in *N. asteroides/brasiliensis* and *Streptomyces madurae* infections) \[[@B19-dentistry-07-00085]\]. If possible, these sulfur granules from the sinuses or tissue biopsy should be crushed and examined microscopically after Gram-staining (or methylene blue), where Gram-positive, thin rods should be observed with a branching morphology. These bacterial cells may also be surrounded by inflammatory (polymorphonuclear leukocytes, PMN) cells, plasma cells and fibroblasts \[[@B1-dentistry-07-00085]\]. Histological examination of tissue samples is also an important cornerstone of diagnosis. Various staining methods, such as periodic acid-Schiff staining, hematoxylin-eosin, Gömöri's methenamine silver stain, and fluorescein-conjugated specific antibodies may be used for this purpose \[[@B1-dentistry-07-00085]\]. Histological examination detects the characteristic granules and bacterial mycelia in \~75% of cases \[[@B19-dentistry-07-00085]\]. Cytology is the most sensitive method for the detection of *Actinomyces* spp. in suspected pelvic actinomycosis \[[@B26-dentistry-07-00085]\]. Although they may not be contributory to the establishment of positive diagnosis, imaging technologies may be useful in the differentiation of suppurative lesions caused by *Actinomyces* from malignancy \[[@B29-dentistry-07-00085],[@B44-dentistry-07-00085],[@B45-dentistry-07-00085],[@B46-dentistry-07-00085],[@B73-dentistry-07-00085],[@B90-dentistry-07-00085],[@B91-dentistry-07-00085],[@B92-dentistry-07-00085],[@B93-dentistry-07-00085]\]. Dental panoramic radiographs, computer tomography (CT), and magnetic resonance imaging (MRI) are also valuable in the evaluation of the extent of tissue involvement (whether bone tissue is involved) and size and location of the granulomatous lesion \[[@B29-dentistry-07-00085],[@B44-dentistry-07-00085],[@B45-dentistry-07-00085],[@B46-dentistry-07-00085],[@B73-dentistry-07-00085],[@B90-dentistry-07-00085],[@B91-dentistry-07-00085],[@B92-dentistry-07-00085],[@B93-dentistry-07-00085]\] ([Figure 1](#dentistry-07-00085-f001){ref-type="fig"}).

5. Therapy of Actinomycoses {#sec5-dentistry-07-00085}
===========================

When considering the antimicrobial therapy of *Actinomyces* infections, clinicians should be aware of the antibiotics having anti-anaerobe activity \[[@B94-dentistry-07-00085]\]. The complete list of these antibiotics, the rationale behind their clinical efficacy and global resistance levels are beyond the scope of this review, for further reading, see another publication by the authors \[[@B18-dentistry-07-00085]\]. Anaerobes with a high oxygen tolerance due to the presence of various enzymes (i.e., *Actinobaculum, Actinomyces, Bifidobacterium, Lactobacillus, Propionibacterium*) or strictly anaerobic genera (e.g., *Atopobium, Eggerthella, Eubacterium*, and *Mobiluncus*) due to other mechanisms are intrinsically resistant to metronidazole, which is considered to be the therapy-of-choice for other anaerobic genera (e.g., *B. fragilis*, *Clostridium* species) \[[@B95-dentistry-07-00085],[@B96-dentistry-07-00085]\]. Aminoglycosides have no activity against anaerobes in general (including *Actinomyces*), while fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin), sulfamethoxazole/trimethoprim are usually considered to be inactive \[[@B97-dentistry-07-00085],[@B98-dentistry-07-00085]\]. Among β-lactam antibiotics, penicillinase-stable penicillins (such as oxacillin and cloxacillin), first generation cephalosporins (cephalexin) and aztreonam are also ineffective. Doxycycline could be considered as a viable therapeutic option (and there are several reports of clinical success with this drug); however, resistance levels in anaerobes globally are very high, discouraging the use of this agent in first-line therapy \[[@B18-dentistry-07-00085],[@B32-dentistry-07-00085],[@B99-dentistry-07-00085]\].

The first-line therapy of actinomycosis is high-dose therapy with intravenous penicillin G (12--24 million U/day for adults) or ampicillin for 2--6 weeks, which should be replaced in a sequential fashion (and if clinical improvement is observed) by penicillin V or amoxicillin *per os* for an extended period of time (6--12 months) to prevent relapse \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B19-dentistry-07-00085],[@B100-dentistry-07-00085]\]. If it is clinically reasonable, intravenous agents may include more broad-spectrum agents, such as piperacillin-tazobactam, cefoxitin, ceftriaxone, and carbapenems. In the case of penicillin-hypersensitivity, other drugs should be considered: clindamycin (good penetration into abscesses), macrolides (erythromycin, clarithromycin, or azithromycin), doxycycline, tigecycline, and chloramphenicol \[[@B27-dentistry-07-00085],[@B101-dentistry-07-00085],[@B102-dentistry-07-00085],[@B103-dentistry-07-00085]\]. In actinomycoses, the elimination of *Actinomyces* spp. is generally considered to be adequate for clinical cure, however in severe cases or for immunosuppressed patients, antibiotic therapy should target all isolated species \[[@B11-dentistry-07-00085]\]. If polymicrobial infection is suspected, a β-lactam/β-lactamase-inhibitor combination, carbapenems, aminoglycosides (e.g., for *Enterobacteriaceae*), or metronidazole (against other anaerobes) should also be administered in the therapeutic regimen \[[@B41-dentistry-07-00085]\]. However, the dogma of prolonged therapy in actinomycoses has been challenged by several reports, where shorter (1--4 week) therapeutic regimens were also reported to be successful \[[@B104-dentistry-07-00085],[@B105-dentistry-07-00085],[@B106-dentistry-07-00085]\] ([Table 4](#dentistry-07-00085-t004){ref-type="table"}). Especially in mild cases (i.e., no bone involvement) of cervicofacial and thoracic actinomycoses, satisfactory cure rates have been observed with short-term oral-only antibiotic therapy, coupled with proper surgical debridement, without relapses. Nevertheless, more clinical studies are required to warrant a change in current therapeutic guidelines, as this topic is still very controversial \[[@B104-dentistry-07-00085],[@B105-dentistry-07-00085],[@B106-dentistry-07-00085]\].

Resistance levels of anaerobic bacteria are generally considered to be predictable, and because of this, routine antimicrobial susceptibility testing is not indicated in *Actinomyces* spp., only for reference laboratories for surveillance purposes \[[@B107-dentistry-07-00085],[@B108-dentistry-07-00085]\]. The gold standard method for antimicrobial susceptibility testing of anaerobes is the agar dilution method (recommended by the Clinical and Laboratory Standards Institute; CLSI), which is a very expensive and labor-intensive technique, recommended for anaerobic reference centers \[[@B109-dentistry-07-00085],[@B110-dentistry-07-00085]\]. Drug resistance (excluding intrinsic resistance mechanisms) is not a relevant issue in *Actinomyces* species, as their susceptibility levels to penicillin, amoxicillin, piperacillin-tazobactam, ceftriaxone, and carbapenems is near 100%, although the use of broad-spectrum agents is discouraged if additional etiologies are not considered \[[@B48-dentistry-07-00085],[@B107-dentistry-07-00085],[@B108-dentistry-07-00085]\]. However, some minor differences between *Actinomyces* species have been observed: while these microorganisms do not produce β-lactamases, *bla*~TEM~-type β-lactamases were detected in *A. graevenitzii* and *A. europaeus*, conferring resistance to ceftriaxone and piperacillin-tazobactam \[[@B107-dentistry-07-00085],[@B111-dentistry-07-00085]\]. Additionally, there have been reports of *Actinomyces* spp. with high minimum inhibitory concentrations for tetracycline and meropenem \[[@B19-dentistry-07-00085]\]. Despite prolonged therapy with large doses of antibiotics, recurrence actinomycoses is common; however, this problem is more pertaining to pharmacokinetics (i.e., poor tissue penetration of antibiotics in the inflamed tissue, inadequate blood supply, and production of biofilm), and presumably not related to drug resistance \[[@B107-dentistry-07-00085],[@B108-dentistry-07-00085]\].

Although antibiotic therapy is the basis of *Actinomyces* infections, surgical interventions should also be considered \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B19-dentistry-07-00085]\]. In mild cases, surgery may have an adjunctive role in therapy (as debridement reduces the formation of scar tissue) and may reduce the duration and dose of antibiotic treatment required. However, in severe cases, drainage of the formed abscesses to relieve obstruction, excision of sinus tracts, fistulas, and necrotic tissues is required for clinical success. Imaging techniques may be used to monitor response to treatment \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B19-dentistry-07-00085],[@B92-dentistry-07-00085]\]. Additionally, the presence of any malignancy can be also ruled out during surgical intervention. There are several reports on the therapeutic use of photodynamic therapy and laser therapy; however, the relevance of these techniques in clinical practice should be further evaluated \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B19-dentistry-07-00085],[@B100-dentistry-07-00085]\]. For the prevention of cervicofacial actinomycoses, good oral hygiene practices, regular dental checkups (especially for patients with dental prostheses), and specific lifestyle choices (pharmacological control of diabetes, cessation of smoking, reduced alcohol intake) are recommended.

6. Conclusions {#sec6-dentistry-07-00085}
==============

Due to its relatively rare occurrence, human *Actinomyces* infections are considered to be a neglected disease (the WHO does not maintain a current statistical database on the global prevalence of actinomycoses); however, due to an increase in the number of immunocompromised patients and the wider availability of dental procedures worldwide, the prevalence of this illness is thought to be increasing. Especially in the case of cervicofacial actinomycosis (the most prevalent form of the disease), clinicians---from primary care physicians to surgeons---dentists and clinical microbiologists should familiarize themselves with this condition to allow for its prevention (in the presence of relevant risk factors) appropriate diagnosis and therapy. The distinction between actinomycosis and other infectious (tuberculosis, nocardiosis, fungal infections) and non-infectious (tumors) pathologies should be the first diagnostic step, and all relevant diagnostic modalities should be utilized. Because culture results and the presence of the characteristic sulfur granules is not specific enough for definitive diagnosis, the underlying conditions and present symptoms of the patient should be consulted. Patients usually present with extensive tissue damage and severe symptoms, due to the slow progression and indolent nature of the disease. On a positive note, the response to the adequately long antimicrobial therapy is usually good, even in patients where extensive necrosis and tissue damage has already occurred. Continuous education of healthcare professionals and a high degree of suspicion is imperative for the apt management of *Actinomycosis* infections.

7. Literature Search {#sec7-dentistry-07-00085}
====================

To formulate the present manuscript, a literature search was performed by the authors in the PubMed/MEDLINE, EMBASE, and Web of Science databases up to 30th of May, 2019, using the following search keys: "*Actinomyces* OR *actinomycosis* OR *actinomycoses* OR *lumpy jaw syndrome* OR *A. gerencseriae* OR *A. israelii* OR *A. meyeri* OR *A. odontolyticus*". There were no restrictions on article type or language. Two independent authors (M.G. and G.T.) examined the search results and selected papers based on the suitability to be included in this review paper. After the selection of appropriate articles, the reference list of these papers was also screened for relevant papers in the topic. Additionally, in case of several sub-topics of the review (e.g., MALDI-TOF for the diagnostics of anaerobes), authors also used references from their personal collection, totaling in n = 111 references.
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AIDS

acquired immunodeficiency syndrome

CNS

central nervous system

CRP

C-reactive protein

CT

computer tomography

DNA

deoxyribonucleic acid

ESR

erythrocyte sedimentation rate

G+C

guanine-cytosine content

GPAC

Gram-positive anaerobic cocci

HIV

human immunodeficiency virus

HMP

Human Microbiome Project

IUD

intrauterine device

MALDI-TOF MS

matrix-assisted laser desorption/ionization time-of flight mass spectrometry

MRI

magnetic resonance imaging

NSAID

non-steroidal anti-inflammatory drugs

NGS

next-generation sequencing

NIH

National Institutes of Health

PCR

polymerase chain reaction

PMN

polymorphonuclear neutrophils

PRAS

pre-reduced anaerobically sterilized

WHO

World Health Organization

![Schematic diagnostic algorithm for the clinical diagnosis of *Actinomyces* infections (for detailed explanation, see [Section 2](#sec2-dentistry-07-00085){ref-type="sec"}, [Section 3](#sec3-dentistry-07-00085){ref-type="sec"} and [Section 4](#sec4-dentistry-07-00085){ref-type="sec"}).](dentistry-07-00085-g001){#dentistry-07-00085-f001}

dentistry-07-00085-t001_Table 1

###### 

*Actinomyces* species implicated in human infections \[[@B1-dentistry-07-00085],[@B3-dentistry-07-00085],[@B5-dentistry-07-00085],[@B7-dentistry-07-00085],[@B8-dentistry-07-00085],[@B10-dentistry-07-00085],[@B11-dentistry-07-00085]\].

  ----------------------- --------------------- ------------------------ ------------------------------
  *A. bovis*              *A. graevenitzii*     *A. nasicola*            *A. radingae*
  *A. cardiffiensis*      *A. hominis*          *A. neuii*               *A. timonensis*
  *A. dentalis*           *A. hongkongiensis*   ***A. odontolyticus***   *A. turicensis*
  *A. europaeus*          ***A. israelii***     *A. oris*                *A. urogenitalis*
  *A. funkei*             *A. massiliensis*     *A. oricola*             *A. viscous*
  *A. georgiae*           ***A. meyeri***       *A. pyogenes*            *several novel geno-species*
  ***A. gerencseriae***   *A. naeslundii*       *A. radicidentis*        
  ----------------------- --------------------- ------------------------ ------------------------------

Species in ***boldface*** represent \>90% of species isolated from human infections; *A. odontolyticus* and *A. meyeri* are more frequently implicated in infections of the cervicofacial region, while *A. gerencseriae* and *A. israelii* are prevalent in all types of actinomycoses.

dentistry-07-00085-t002_Table 2

###### 

Clinical manifestations of *Actinomyces* infections \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B11-dentistry-07-00085],[@B19-dentistry-07-00085],[@B21-dentistry-07-00085],[@B22-dentistry-07-00085],[@B23-dentistry-07-00085],[@B24-dentistry-07-00085],[@B25-dentistry-07-00085],[@B26-dentistry-07-00085],[@B27-dentistry-07-00085],[@B28-dentistry-07-00085],[@B29-dentistry-07-00085],[@B30-dentistry-07-00085],[@B31-dentistry-07-00085]\].

  ------------------------------------------------------------------------------------------ ---------
  *Cervicofacial (including Central Nervous System (CNS))*                                   40--60%
  *[Affected areas:]{.ul}*                                                                   
  Upper and lower mandibles                                                                  50%
  Cheeks                                                                                     10--15%
  Chin                                                                                       10--15%
  Submaxillary ramus and angle, mandibular joints                                            5--10%
  CNS (brain abscess, meningitis, meningoencephalitis, epidural abscess, subdural empyema)   5--10%
  Tongue, sinuses, middle ear, larynx, lachrymal pathways, and thyroid gland                 0--5%
  *Abdominal*                                                                                20--30%
  *Thoracic (incl. pulmonary)*                                                               20--25%
  *Pelvic*                                                                                   3--5%
  *Cutaneous*                                                                                3--5%
  ------------------------------------------------------------------------------------------ ---------

dentistry-07-00085-t003_Table 3

###### 

General and disease-specific risk factors for cervicofacial actinomycosis \[[@B1-dentistry-07-00085],[@B5-dentistry-07-00085],[@B11-dentistry-07-00085],[@B19-dentistry-07-00085],[@B21-dentistry-07-00085],[@B22-dentistry-07-00085],[@B23-dentistry-07-00085],[@B24-dentistry-07-00085],[@B25-dentistry-07-00085],[@B26-dentistry-07-00085],[@B27-dentistry-07-00085],[@B28-dentistry-07-00085],[@B29-dentistry-07-00085],[@B41-dentistry-07-00085],[@B42-dentistry-07-00085],[@B43-dentistry-07-00085]\].

  General                                                                                            Disease-Specific
  -------------------------------------------------------------------------------------------------- ---------------------------------
  Human Immunodeficiency Virus (HIV) infection or manifest AIDS                                      Erupting secondary teeth
  Hematological malignancies or solid tumors                                                         Poor dental hygiene
  Organ transplantation (especially in case of the kidneys and lungs)                                Dental caries
  Use of monoclonal antibodies (e.g., anti-tumor necrosis-α-inhibitors, infliximab, etanercept)      Gingivitis
  Cancer chemotherapy                                                                                Mucositis
  Corticosteroid use                                                                                 Dental extraction
  Malnutrition                                                                                       Introduction of dental implants
  Diabetes                                                                                           Cervicofacial surgery
  Alcoholism                                                                                         Traumatic injury
  Smoking and/or inhalation of particles                                                             Bisphosphonate therapy
  Low socio-economic status                                                                          Radiation therapy
  Seizure disorders                                                                                  
  Crohn's disease                                                                                    
  Hereditary diseases (e.g., hereditary hemorrhagic telangiectasia, chronic granulomatous disease)   
  Use of non-steroid anti-inflammatory drugs (NSAIDs)                                                

dentistry-07-00085-t004_Table 4

###### 

Therapeutic considerations for *Actinomyces* infections.

  --------------------------------------------------------------------------- ------------------------------------------------------
  **Antibiotic Therapy**                                                      
  **Should be Considered**                                                    **Should NOT be Considered**
  Penicillin G                                                                Metronidazole \*
  Penicillin V                                                                Aminoglycosides \*
  Ampicillin                                                                  Other β-lactam-β-lactamase-inhibitor combinations \*
  Amoxicillin                                                                 Penicillinase-stable penicillins
  Piperacillin/tazobactam                                                     First generation cephalosporins (cephalexin)
  Second generation cephalosporins with anti-anaerobic activity (cefoxitin)   Aztreonam \*
  Third generation cephalosporins (ceftriaxone)                               Sulfamethoxazole/trimethoprim \*
  Carbapenems                                                                 Fluoroquinolones \*
  Doxycycline                                                                 
  Tigecycline                                                                 
  Clindamycin                                                                 
  Macrolides                                                                  
  Chloramphenicol                                                             
  **Adjunctive Therapy**                                                      
  Surgical debridement, drainage                                              
  Photodynamic therapy                                                        
  Laser therapy                                                               
  --------------------------------------------------------------------------- ------------------------------------------------------

\* Should be reconsidered in case of polymicrobial infections (e.g., *Enterobacteriaceae*, other anaerobes).
